Sergio Cifuentes, Medical Oncologist at Las Américas Auna Clinic, shared a post on X:
“HER2 in mCRC Treatment – Chemotherapy+Bevacizumab
- In 8 RCTs of mCRC, 5% were HER2+
- HER2+ patients had shorter PFS (9.8 vs 12.2 mo, HR 1.31) and OS (28.0 vs 34.9 mo, HR 1.37)
- ORR was similar (75% vs 72%)
- HER2-mutant (2%) also showed shorter OS (23.7 vs 34.4 mo, HR 1.56).”
More posts featuring Sergio Cifuentes.